Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    Anavex Life Sciences Provides Update On Regulatory Review In The EU For Blarcamesine To Treat Early Alzheimer's Disease

    21 hours ago

    (MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (–Anavex– or the–Company–) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company ...
    Click here to Read More
    Previous Article
    Fredonia Mining Inc. Engages ICP Securities Inc. For Automated Market Making Services And Enters Into Investor Relations And Capital Markets Advisory Agreement
    Next Article
    Delphx Announces Grant Of Stock Options

    Related World Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment